Compare JYNT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | LUNG |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Industrial Specialties |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.2M | 97.1M |
| IPO Year | 2014 | 2020 |
| Metric | JYNT | LUNG |
|---|---|---|
| Price | $8.42 | $2.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $17.00 | $5.38 |
| AVG Volume (30 Days) | 61.1K | ★ 894.6K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.93 | 7.64 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $117,696,356.00 | $90,497,000.00 |
| Revenue This Year | $12.23 | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $60.07 | ★ N/A |
| Revenue Growth | ★ 15.49 | 8.01 |
| 52 Week Low | $7.50 | $1.13 |
| 52 Week High | $10.74 | $2.89 |
| Indicator | JYNT | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 66.26 |
| Support Level | $8.07 | $1.27 |
| Resistance Level | $9.49 | $2.66 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 43.75 | 68.87 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.